IONS: financial statements from SEC — TradeAlmanac

IONS

Ionis Pharmaceuticals, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Revenue	246m	—	157m	452m	132m	—	134m	225m
Cost of revenue	3m	—	2m	4m	1m	—	1m	4m
Selling, general and administrative	150m	—	97m	91m	76m	—	62m	65m
Operating expenses	364m	418m	317m	312m	278m	337m	282m	291m
Operating income	−117m	−214m	−160m	140m	−147m	−111m	−149m	−66m
Interest expense	5m	—	4m	4m	4m	—	4m	4m
Pre-tax income	−92m	—	−128m	124m	−147m	—	−144m	−66m
Income tax	218,000	—	213,000	−20,000	116,000	—	−4m	64,000
Net income	−93m	−229m	−129m	124m	−147m	−104m	−140m	−66m
Earnings per share	−0.56	−1.41	−0.80	0.78	−0.93	−0.66	−0.95	−0.45
Earnings per share, diluted	−0.56	−1.41	−0.80	0.70	−0.93	−0.66	−0.95	−0.45
Weighted average shares	165m	—	160m	159m	159m	—	149m	146m
Weighted average shares, diluted	165m	—	160m	182m	159m	—	149m	146m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	173m	372m	338m	297m	264m	242m	335m	294m
Short-term investments	1.75bn	2.31bn

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−793m	−151m
Depreciation and amortisation	3m	2m
Share-based compensation	43m	30m
Capital expenditure	22m	13m
Investing cash flow	537m	170m
Financing cash flow	57m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)